JAMA Dermatology Trial: Text Nudges Cut Heart Risk in Psoriasis

A randomized clinical trial published online May 14, 2026 in [JAMA Dermatology](https://jamanetwork.com/journals/jamadermatology/article-abstract/2848886){rel="nofollow noopener" target="_blank"} found that a structured text-messaging program produced measurable, sustained gains in cardiovascular risk-reduction behaviors among adults living with psoriasis. The TEXTME PSO trial assigned participants to receive either targeted lifestyle messages or generic appointment reminders, and the intervention arm finished the study with Patient Activation Measure (PAM-13) scores 10.8 points higher than controls. Eighty percent of intervention participants reached the highest two engagement tiers, compared with 51% at baseline. ## Why the Dermatology Visit Has Become a Cardiovascular Touchpoint Psoriasis is a chronic, immune-mediated inflammatory disease that produces well-demarcated plaques on the skin, but its biology does not stop at the epidermis. The same cytokine signaling that drives plaque formation, particularly the IL-23 to IL-17 axis, the same cytokine pathway implicated in other [chronic inflammatory skin disease research](/science/hidradenitis-suppurativa-environmental-drivers-2026/), also promotes endothelial dysfunction, accelerates atherosclerotic plaque development, and disrupts lipid metabolism. [Population data](https://jamanetwork.com/collections/5870/psoriasis){rel="nofollow noopener" target="_blank"} have shown for more than a decade that adults with moderate-to-severe psoriasis carry roughly a 50% higher risk of major cardiovascular events than the general population, and the relative risk climbs further in patients diagnosed in young adulthood. That epidemiology has reframed the dermatology visit. For many psoriasis patients, the dermatologist is the clinician they see most consistently, often more than primary care. Yet routine cardiovascular risk counseling has remained inconsistent in dermatology practice, with most clinics defaulting to plaque-clearance metrics and leaving systemic risk management to other specialists. The TEXTME PSO investigators set out to test whether a structured, low-cost behavioral intervention delivered through phones could close that gap. The intervention messages were evidence-based and tonally motivational. Content covered Mediterranean diet patterns, weekly physical activity targets, smoking cessation, weight management, and adherence to prescribed psoriasis treatment, with periodic embedded education on the link between psoriasis and cardiovascular disease. Controls received three generic text messages per week, limited to appointment reminders and clinic contact information. ## How Large Was the Behavior Change in TEXTME PSO? The Patient Activation Measure, a 13-item validated instrument that scores patients from 1 to 100 across four tiers of self-management engagement, served as the primary outcome. The intervention group exceeded controls by 10.8 PAM points by study end, a difference the authors describe as clinically meaningful and consistent with the magnitude observed in earlier text-messaging trials for diabetes and hypertension, as [summarized by Healio](https://www.healio.com/news/dermatology/20260514/text-message-nudges-improved-hearthealthy-behaviors-among-people-with-psoriasis){rel="nofollow noopener" target="_blank"}. Eighty percent of intervention participants finished the trial at PAM level 3 or 4, the two highest engagement tiers, compared with 51% at baseline. Secondary endpoints reinforced the primary signal. Intervention participants logged about 128 more minutes of weekly exercise than controls, recorded a larger decrease in body mass index, and reported higher rates of Mediterranean diet adherence and medication adherence. Self-reported knowledge of both psoriasis and cardiovascular disease was also higher in the intervention arm. The findings were published in JAMA Dermatology with the citation doi:10.1001/jamadermatol.2026.1070. ## What This Means for Patients Managing Inflammatory Skin Disease For readers with psoriasis or other chronic inflammatory skin conditions, the practical implication is that the dermatology relationship is a meaningful entry point for whole-body health, not only for plaque-clearance metrics. The TEXTME PSO data suggest that even brief, structured outside-visit communication can shift the trajectory of exercise, diet, and adherence behavior, and that effect appears to be durable across the trial period rather than collapsing back to baseline within weeks, an outcome durability worth noting alongside other recent [JAMA Dermatology population studies](/science/pediatric-skin-disease-frequencies-race-ethnicity-2026/). Three takeaways follow. Routine cardiovascular screening, including lipid panels, blood pressure measurement, and discussion of metabolic risk, deserves a place in psoriasis follow-up, and patients can reasonably ask their dermatologist about it. Lifestyle interventions show meaningful effect sizes in this population, which is consistent with the broader literature linking systemic inflammation reduction to cardiovascular outcomes. And the digital channel itself, text messaging, is now backed by randomized evidence in a dermatology population, which lowers the barrier for clinics to deploy similar programs. The trial does not change first-line psoriasis treatment selection. Biologics targeting IL-17 and IL-23 remain the standard for [moderate-to-severe disease](/science/jama-global-skin-cancer-burden-2050/), and the cardiovascular benefits of effective disease control through pharmacotherapy are well documented. What TEXTME PSO adds is evidence that a parallel, low-cost behavioral track is achievable and worth integrating. ## When Will Programs Like This Reach Routine Practice? Translation will depend on infrastructure rather than science. Text-messaging platforms exist in most large dermatology networks, and the message content used in TEXTME PSO can be adapted without proprietary licensing. The next research questions are about durability beyond the trial window, generalizability across racial and socioeconomic subgroups, and whether the intervention reduces hard cardiovascular endpoints rather than only intermediate behavioral and biometric measures. Larger, longer trials are the logical next step, and the authors signal that prospective expansion is already being planned. In the near term, expect academic dermatology centers and integrated health systems to pilot similar programs first. For patients, the actionable step is to raise the cardiovascular conversation at the next dermatology visit and to ask whether the practice offers structured between-visit support.